Northern Blotting Market Trends

Growth Drivers  

• Government and Medicare spending: Medicare spending on northern blotting market diagnostic in 2023 has reached USD 811.4 million, which is an increase of 16.2% from 2021. This rise is due to the expanded reimbursement policies of CMS targeting molecular diagnostic technologies. Further, Medicaid also expanded its coverage impacting patients of 250,010 positively across multiple states for those who are affected by cancer and other rare diseases. These improvements in policies are driving the market with broader adoption in both clinical and academic research settings.

• Healthcare quality improvement: As per the AHRQ report, the early stage implementation of RNA hybridization methods has reduced by 21.7% by using northern blotting techniques and has saved an amount of USD 1.5 billion in healthcare costs over the past two years. The report has also stated that there is an improvement in patient outcomes and faster diagnosis rates in oncology and infectious disease applications. AHRQ's emphasis on cost-effectiveness has led a number of institutions in the United States to include Northern blotting into their standard molecular pathology procedures.

Challenges

Government price caps and cost containment policies: The Government imposes robust pricing limitations to minimize the national healthcare spending. For example, countries in Europe, including France, have imposed a price ceiling in the national health reimbursement framework. Further companies are collaborating with French health authorities to offer high pricing, which led to a 10.5% hike in market access. This pricing strategy enabled manufacturers to maintain profit while aligning with France’s health economic evaluations under CEPS. Furthermore, as part of larger EU pricing harmonization initiatives under the European Pharmaceutical Strategy, comparable approaches are being examined in Germany and Italy.